Half-year report · Q2
4539.TEDINET S100UPF3
Period2024-04-01 → 2024-09-30
Filed2024-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥15.6bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥30.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥14.8bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | ¥76m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | −¥298m | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | −¥62m | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | −¥219m | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥10m | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | −¥62m | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥27m | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥44m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥180m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥31m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥44m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | ¥31m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥52.0bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥49.5bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥50.9bn | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥33.5bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥31.1bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥18.6bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥18.5bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥18.5bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥10.8bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥9.2bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥10.8bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥9.2bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥11.3bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.5bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥702m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥296m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥592m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥88m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥3.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.4bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥974m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.5bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-12.26 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-50.14 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥8.72 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 35.7% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.3% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.5% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 28
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2024-09-30 | ¥627m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2024-09-30 | ¥570m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥56m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2024-09-30 | ¥38m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥61m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥61m |
| jpcrp040300-q2r_E00957-000Medicinereportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥15.1bn |
| jpcrp040300-q2r_E00957-000Medicinereportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥15.1bn |
| jpcrp040300-q2r_E00957-000Medicinereportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥4m |
| jpcrp040300-q2r_E00957-000Medicinereportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥38m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥15.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥15.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥61m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥76m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2023-09-30 | ¥546m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2023-09-30 | ¥544m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥2m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-09-30 | ¥56m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥5m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥5m |
| jpcrp040300-q2r_E00957-000Medicinereportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥14.3bn |
| jpcrp040300-q2r_E00957-000Medicinereportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥14.3bn |
| jpcrp040300-q2r_E00957-000Medicinereportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥3m |
| jpcrp040300-q2r_E00957-000Medicinereportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥355m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥14.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥14.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥5m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | −¥298m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 534
| Item | Context | Value | Unit |
|---|---|---|---|
| Net cash provided by used in investment activities | Prior1YTDDuration | -1418000000 | JPY |
| Net cash provided by used in investment activities | CurrentYTDDuration | -88000000 | JPY |
| Net increase decrease in short term loans payable fin cf | Prior1YTDDuration | 40000000 | JPY |
| Net increase decrease in short term loans payable fin cf | CurrentYTDDuration | -266000000 | JPY |
| Proceeds from long term loans payable fin cf | Prior1YTDDuration | 3100000000 | JPY |
| Proceeds from long term loans payable fin cf | CurrentYTDDuration | 2850000000 | JPY |
| Repayment of long term loans payable fin cf | Prior1YTDDuration | -1367000000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYTDDuration | -1382000000 | JPY |
| Cash dividends paid fin cf | Prior1YTDDuration | -182000000 | JPY |
| Cash dividends paid fin cf | CurrentYTDDuration | -182000000 | JPY |
| Other net fin cf | Prior1YTDDuration | -41000000 | JPY |
| Other net fin cf | CurrentYTDDuration | -45000000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | 1548000000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | 974000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YTDDuration | 69000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYTDDuration | 16000000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | 791000000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | 1604000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 10529000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 9200000000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 11321000000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 10805000000 | JPY |
| Advertising expenses sga | Prior1YTDDuration | 37000000 | JPY |
| Advertising expenses sga | CurrentYTDDuration | 33000000 | JPY |
| Traveling and transportation expenses sga | Prior1YTDDuration | 174000000 | JPY |
| Traveling and transportation expenses sga | CurrentYTDDuration | 160000000 | JPY |
| Salaries sga | Prior1YTDDuration | 1252000000 | JPY |
| Salaries sga | CurrentYTDDuration | 1256000000 | JPY |
| Retirement benefit expenses sga | Prior1YTDDuration | 31000000 | JPY |
| Retirement benefit expenses sga | CurrentYTDDuration | 37000000 | JPY |
| Commission fee sga | Prior1YTDDuration | 616000000 | JPY |
| Commission fee sga | CurrentYTDDuration | 620000000 | JPY |
| Research and development expenses sga | Prior1YTDDuration | 1006000000 | JPY |
| Research and development expenses sga | CurrentYTDDuration | 1160000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E00957-000MedicineReportableSegmentsMember | 14293000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 544000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 14837000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 14837000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E00957-000MedicineReportableSegmentsMember | 3000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 2000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 5000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -5000000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00957-000MedicineReportableSegmentsMember | 14297000000 | JPY |
| Net sales | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 546000000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 14843000000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -5000000 | JPY |
| Net sales | Prior1YTDDuration | 14837000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00957-000MedicineReportableSegmentsMember | -355000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |